

**ANUH PHARMA LTD.**  
CIN: L24230MH1960PLC011586


Regd. Office : 3-A, North Wing, Shivsagar Estate, Dr. Annie Besant Road, Worli, Mumbai - 400018  
Tel: +91 22 6622 7575; Fax: +91 22 6622 7600; Email: anuh@sk1932.com; Website: www.anuhpharma.com

**UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30<sup>TH</sup> JUNE, 2018**

(Rs. in Lakhs)

Sr. No.	Particulars	3 months ended 30/06/2018	3 months ended 31/03/2018	3 months ended 30/06/2017	12 months ended 31/03/2018
		Unaudited	Audited (Refer note. 2)	Unaudited	Audited
I.	Revenue from operations (Refer note. 3)	8,024.87	6,709.76	5,495.40	24,123.59
II.	Other income	114.74	154.34	339.29	738.98
III.	<b>Total Revenue (I + II)</b>	<b>8,139.61</b>	<b>6,864.10</b>	<b>5,834.69</b>	<b>24,862.57</b>
IV.	Expenses:				
	Cost of materials consumed	6,414.39	5,157.69	3,872.19	18,372.29
	Purchases of Stock-in-Trade	-	24.65	-	34.62
	Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(270.25)	(135.94)	10.38	(327.74)
	Employee benefits expense	237.88	260.93	199.29	900.11
	Finance costs	0.77	3.61	0.03	4.05
	Depreciation and amortization expense	35.22	52.15	41.50	183.15
	Excise duty	-	-	315.92	315.92
	Other expenses	952.26	1,020.22	627.77	3,038.46
	<b>Total expenses (IV)</b>	<b>7,370.27</b>	<b>6,383.31</b>	<b>5,067.08</b>	<b>22,520.86</b>
V.	<b>Profit / (Loss) before exceptional and items and tax (III - IV)</b>	<b>769.34</b>	<b>480.79</b>	<b>767.61</b>	<b>2,341.71</b>
VI.	Exceptional items	-	-	-	-
VII.	<b>Profit / (Loss) before tax (V - VI)</b>	<b>769.34</b>	<b>480.79</b>	<b>767.61</b>	<b>2,341.71</b>
VIII.	Tax expense:				
	(1) Current tax	212.80	193.00	142.00	686.00
	(2) Deferred tax	(13.19)	(37.74)	-	4.47
		<b>199.61</b>	<b>155.26</b>	<b>142.00</b>	<b>690.47</b>
IX.	<b>Profit/(Loss) after Tax (VII-VIII)</b>	<b>569.73</b>	<b>325.53</b>	<b>625.60</b>	<b>1,651.24</b>
X.	Other Comprehensive Income (net of Tax)				
	(i) Items that will not be reclassified to profit or loss	(0.03)	(5.25)	6.01	5.18
	(ii) Items that will be reclassified to profit or loss		-	-	-
	<b>Total Other Comprehensive Income (net of Tax)</b>	<b>(0.03)</b>	<b>(5.25)</b>	<b>6.01</b>	<b>5.18</b>
XI.	<b>Total Comprehensive Income for the period (IX + X) (Comprising Profit / (Loss) and Other Comprehensive Income for the period)</b>	<b>569.70</b>	<b>320.28</b>	<b>631.62</b>	<b>1,656.42</b>
	Paid up Equity Share Capital (Face value ₹ 5/- each)	1,252.80	1,252.80	1,252.80	1,252.80
	Other Equity (excluding revaluation reserves)				13,708.72
XII.	Earnings per equity share (Non annualised) (In Rs.)				
	(1) Basic	2.27	1.30	2.50	6.59
	(2) Diluted	2.27	1.30	2.50	6.59

See accompanying notes to the financial results



1. The results of the quarter ended 30th June, 2018 were reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on 11th August, 2018. They have been subjected to limited review by the Statutory Auditor.
2. The figures for the quarter ended 31<sup>st</sup> March, 2018 are balancing figures between the audited figures in respect of the full financial year and the published year to date figures upto nine months period ended on 31st December, 2017.
3. Revenue from operations for the quarter ended 30<sup>th</sup> June, 2018 and 31st March, 2018 is net of Goods & Service Tax (GST), however revenue from operations till period ended 30th June, 2017 and 31st March, 2018 are gross of excise duty. Hence, the revenue from operations for the quarter ended 30th June, 2018 are not comparable with quarter ended 30th June, 2017.
4. The Company has identified Bulk drug and Chemicals as its only primary reportable segment in accordance with the requirements of Ind AS 108, 'Operating Segments'. Accordingly, no-separate segment information has been provided.

**5. Key numbers of the results are as under:**

(Rs. in Lakhs)


PARTICULARS	3 months ended 30/06/2018	3 months ended 31/03/2018	3 months ended 30/06/2017	12 months ended 31/03/2018
	Unaudited	Audited	Unaudited	Audited
Profit before tax as per above results	769.34	480.79	767.61	2,341.71
Add/ less :-				
Mark to market loss/ (gain)on Investment	63.97	86.04	(65.42)	222.25
Less :- Realised Investment Income realised	114.74	154.34	242.42	738.98
Profit before tax (from operations)	718.57	412.48	459.77	1,824.97

6. Previous period's figures have been regrouped and reclassified, wherever necessary, to correspond with those of the current period.

For Anuh Pharma Limited



**Bipin N. Shah**  
**Managing Director**  
**(DIN: 00083244)**



Place : Mumbai

Dated : 11th August, 2018

**REVIEW REPORT TO THE BOARD OF DIRECTORS OF**  
**ANUH PHARMA LIMITED**

We have reviewed the accompanying Statement of Unaudited Financial Results of **Anuh Pharma Limited** ("the Company") for the quarter ended 30th June, 2018 ("the Statement") being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016. This Statement is the responsibility of the Company's Management and approved by the Board of Directors. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the applicable Indian Accounting Standards ('Ind AS') specified under Section 133 of the Companies Act, 2013, read with relevant rules issued there under and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**PLACE: Mumbai**  
**DATE: 11<sup>th</sup> August, 2018**



**For JAYANTILAL THAKKAR & CO.**  
**CHARTERED ACCOUNTANTS**  
**(FIRM REG. NO. 104133W)**

*V. A. Merchant*

**VIRAL A. MERCHANT**  
**PARTNER**  
**MEMBERSHIP NO. 116279**